Two doses of deutetrabenazine show efficacy over placebo in treating tardive dyskinesia

The vesicular monoamine transporter‐2 (VMAT2) inhibitor deutetrabenazine at doses of 24 and 36 mg/day demonstrated efficacy compared with placebo in a 12‐week Phase 3 trial in patients with tardive dyskinesia (TD). The results of this study and another trial were instrumental in the Food and Drug Administration's (FDA's) recent decision to approve deutetrabenazine for the TD indication.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: What's New in Research Source Type: research